Abstract:Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1), also known as Parkinson's disease protein 5, is a highly expressed protein in the brain. It plays an important role in the ubiquitin–proteasome system (UPS), where it acts as a deubiquitinase (DUB) enzyme. Being the smallest member of the UCH family of DUBs, it catalyzes the reaction of ubiquitin precursor processing and the cleavage of ubiquitinated protein remnants, thus maintaining the level of ubiquitin monomers in the brain cells. UCHL1 mutants, containing amino acid substitutions, influence catalytic activity and its aggregability. Some of them protect cells and transgenic mice in toxin-induced Parkinson's disease (PD) models. Studies of putative protein partners of UCHL1 revealed about sixty individual proteins located in all major compartments of the cell: nucleus, cytoplasm, endoplasmic reticulum, plasma membrane, mitochondria, and peroxisomes. These include proteins related to the development of PD, such as alpha-synuclein, amyloid-beta precursor protein, ubiquitin-protein ligase parkin, and heat shock proteins. In the context of the catalytic paradigm, the importance of these interactions is not clear. However, there is increasing understanding that UCHL1 exhibits various effects in a catalytically independent manner through protein–protein interactions. Since this protein represents up to 5% of the soluble protein in the brain, PD-related changes in its structure will have profound effects on the proteomes/interactomes in which it is involved. Growing evidence is accumulating that the role of UCHL1 in PD is obviously determined by a balance of canonic catalytic activity and numerous activity-independent protein–protein interactions, which still need better characterization.

The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility

Interaction of the ubiquitin carboxyl terminal esterase L1 with α2-adrenergic receptors inhibits agonist-mediated p44/42 MAP kinase activation

Ubiquitin Carboxyl-Terminal Hydrolase L1 and Its Role in Parkinson's Disease

Membrane-Associated Farnesylated Uch-L1 Promotes Alpha-Synuclein Neurotoxicity and is A Therapeutic Target for Parkinson'S Disease

Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson’s Disease and Neurodegenerative Disorders

Ubiquitin C-terminal Hydrolases L1:Physiological and Pathological Significance

The ubiquitin pathway in Parkinson's disease

The role of polo-like kinases 2 in the proteasomal and lysosomal degradation of alpha-synuclein in neurons

Lipoprotein Lipase Deficiency Leads to Α-Synuclein Aggregation and Ubiquitin C-terminal Hydrolase L1 Reduction.

Case-control study of the UCH-L1 S18Y variant in sporadic Parkinson's disease in Chinese population

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein

Assembly of Lysine 63-Linked Ubiquitin Conjugates by Phosphorylated Α-Synuclein Implies Lewy Body Biogenesis

Polymorphic USP8 Allele Promotes Parkinson’s Disease by Inducing the Accumulation of Α-Synuclein Through Deubiquitination

E46K-like α-synuclein mutants increase lipid interactions and disrupt membrane selectivity

High expression levels of the D686N Parkinson's disease mutation in VPS35 induces α-synuclein-dependent toxicity in yeast

Altered protein dynamics and a more reactive catalytic cysteine in a neurodegeneration-associated UCHL1 mutant

Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

Α‐synuclein Stimulation of Monoamine Oxidase‐b and Legumain Protease Mediates the Pathology of Parkinson's Disease

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Analysis of the UCHL1 Genetic Variant in Parkinson's Disease among Chinese.